| Kathleen J Matthews, ANP | |
|
491 N Knik St, Wasilla, AK 99654-7049 | |
| (907) 376-9500 | |
| (907) 376-9507 |
| Full Name | Kathleen J Matthews |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 35 Years |
| Location | 491 N Knik St, Wasilla, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407878259 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | 407 (Alaska) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 407 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Achieve Medical Alaska Llc | 1951730183 | 5 |
News Archive
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).
A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
› Verified 4 days ago
| Entity Name | Achieve Medical Alaska Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922648690 PECOS PAC ID: 1951730183 Enrollment ID: O20200707001224 |
News Archive
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).
A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
› Verified 4 days ago
| Entity Name | Tms Center Of Alaska Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114454808 PECOS PAC ID: 9830556232 Enrollment ID: O20230530002748 |
News Archive
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).
A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen J Matthews, ANP 491 N Knik St, Wasilla, AK 99654-7049 Ph: (907) 376-9500 | Kathleen J Matthews, ANP 491 N Knik St, Wasilla, AK 99654-7049 Ph: (907) 376-9500 |
News Archive
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).
A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
› Verified 4 days ago
Alysa Sonnentag, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 211 E Fairview Loop, Wasilla, AK 99654 Phone: 907-373-3335 | |
Ms. Lisa Bouyea-francies, APRN-FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1363 W Spruce Ave, Wasilla, AK 99654 Phone: 907-376-2411 Fax: 907-352-3373 | |
Stephanie Rae Mcquillin, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1751 E Gardner Way Ste E, Wasilla, AK 99654 Phone: 907-376-9321 Fax: 907-376-9322 | |
Randall Twenhafel, PNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 950 E Bogard Rd Ste 233, Wasilla, AK 99654 Phone: 907-357-4543 Fax: 907-357-4533 | |
Nancy Mcdonnell Kent, ANP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3223 Palmer Wasilla Hwy, Suite # 3, Wasilla, AK 99654 Phone: 907-352-6600 Fax: 907-376-3096 | |
Mrs. Charlotte M Nelson, A.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4551 E Bogard Rd, Wasilla, AK 99654 Phone: 907-373-6500 Fax: 888-456-0663 | |
Michael Thomas Von Ah, WHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 9761 W Margin Way, Wasilla, AK 99623 Phone: 907-373-5400 Fax: 907-373-5740 |